Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
European League Against Rheumatism (EULAR) Congress 2018
June 13 - 16, 2018; Amsterdam, the Netherlands
June 13 - 16, 2018Amsterdam, the Netherlands
EULAR 2018NSAIDs Increase Cardiovascular Risk in OsteoarthritisNonsteroidal anti-inflammatory drugs contribute to the elevated risk for cardiovascular disease in people with osteoarthritis, new research shows, but alternatives for pain management are limited.
Nonmedical Biosimilar Switch Results Surprise InvestigatorsWhen the Danish government mandated a switch to the infliximab biosimilar, researchers had the perfect opportunity to study
the effect on patients with rheumatologic inflammatory disease.
Medscape Medical News, Jun 30, 2017
Tocilizumab Triumphs in Methotrexate Combo for RAIt is not always clear which biologic to add to methotrexate for rheumatoid arthritis, but a new comparison between tocilizumab
and a number of TNF inhibitors has some suggestions.
Medscape Medical News, Jun 20, 2017
Biologics Comparison in Rheumatoid Arthritis SurprisesA Swedish study had rheumatologists debating the top contenders for second-line therapy in patients with rheumatoid arthritis
who do not respond to TNF inhibitor therapy.
Jonathan Kay, MD UMass Memorial Medical Center, Worcester, Massachusetts Bio Presentation: Impact of immunogenicity on clinical efficacy and administration related reaction in TNF inhibitors: A pooled-analysis
from three biosimilar studies in patients with rheumatoid arthritis Date: June 14, 2018
Muhammed Khan, MD Case Western Reserve University, Cleveland, Ohio Presentation: Occurrence of ankylosing spondylitis among relatives of probands with radiographic and non-radiographic disease
and axial spondyloarthritis Date: June 14, 2018 Presentation: Effect of diacerin vs glucosamine-chondroitin on disease progression, and measures of function in persons with
knee osteoarthritis: A 2-year randomized, double-blink, placebo controlled trial Date: June 16, 2018
Sergio Schwartzman, MD New York-Presbyterian Hospital Presentation: Integrated safety data analysis across phase 3 clinical studies for intravenous golimumab in rheumatoid arthritis,
psoriatic arthritis and ankylosing spondylitis Date: June 15, 2018 Presentation: Efficacy of tofacitinib patients with moderate to severe rheumatoid arthritis by baseline C-reactive protein
levels and erythrocyte sedimentation rates Presentation: Efficacy of baricitinib in patients with rheumatoid arthritis who failed 2 or more DMARDs Date: June 16, 2018